Switch theme
Sign up to access all valuation multiples
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
2008
6.8K+
LTM Revenue $3.0B
LTM EBITDA -$1.4B
$5.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioNTech has a last 12-month revenue of $3.0B and a last 12-month EBITDA of -$1.4B.
In the most recent fiscal year, BioNTech achieved revenue of $2.8B and an EBITDA of -$367M.
BioNTech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioNTech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.8B | $2.8B | XXX | XXX | XXX |
| Gross Profit | $14.3B | $3.2B | XXX | XXX | XXX |
| Gross Margin | 375% | 117% | XXX | XXX | XXX |
| EBITDA | $1.1B | -$367M | XXX | XXX | XXX |
| EBITDA Margin | 28% | -13% | XXX | XXX | XXX |
| Net Profit | $9.4B | $930M | XXX | XXX | XXX |
| Net Margin | 247% | 34% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BioNTech's stock price is $102.
BioNTech has current market cap of $24.6B, and EV of $5.8B.
See BioNTech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.8B | $24.6B | XXX | XXX | XXX | XXX | $-3.82 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BioNTech has market cap of $24.6B and EV of $5.8B.
BioNTech's trades at 2.1x LTM EV/Revenue multiple, and -4.5x LTM EBITDA.
Analysts estimate BioNTech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BioNTech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.8B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | -15.9x | XXX | XXX | XXX |
| P/E | -37.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -23.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioNTech's NTM/LTM revenue growth is -13%
BioNTech's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, BioNTech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BioNTech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BioNTech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -28% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -134% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -27% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 82% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 102% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioNTech acquired XXX companies to date.
Last acquisition by BioNTech was XXXXXXXX, XXXXX XXXXX XXXXXX . BioNTech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BioNTech founded? | BioNTech was founded in 2008. |
| Where is BioNTech headquartered? | BioNTech is headquartered in United States of America. |
| How many employees does BioNTech have? | As of today, BioNTech has 6.8K+ employees. |
| Who is the CEO of BioNTech? | BioNTech's CEO is Professor Ugur Sahin, M.D.. |
| Is BioNTech publicy listed? | Yes, BioNTech is a public company listed on NAS. |
| What is the stock symbol of BioNTech? | BioNTech trades under BNTX ticker. |
| When did BioNTech go public? | BioNTech went public in 2019. |
| Who are competitors of BioNTech? | Similar companies to BioNTech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of BioNTech? | BioNTech's current market cap is $24.6B |
| What is the current revenue of BioNTech? | BioNTech's last 12-month revenue is $3.0B. |
| What is the current EBITDA of BioNTech? | BioNTech's last 12-month EBITDA is -$1.4B. |
| What is the current EV/Revenue multiple of BioNTech? | Current revenue multiple of BioNTech is 2.1x. |
| What is the current EV/EBITDA multiple of BioNTech? | Current EBITDA multiple of BioNTech is -4.5x. |
| What is the current revenue growth of BioNTech? | BioNTech revenue growth between 2023 and 2024 was -28%. |
| Is BioNTech profitable? | Yes, BioNTech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
